These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3283226)

  • 21. Regulation of vasopressin receptors in deoxycorticosterone acetate-salt hypertension.
    Trinder D; Phillips PA; Risvanis J; Stephenson JM; Johnston CI
    Hypertension; 1992 Oct; 20(4):569-74. PubMed ID: 1398892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension.
    Li L; Galligan JJ; Fink GD; Chen AF
    Hypertension; 2003 Mar; 41(3 Pt 2):663-8. PubMed ID: 12623976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
    Intengan HD; He G; Schiffrin EL
    Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of the vascular alpha-1 receptor in malignant DOCA-salt hypertension.
    Meggs LG; Stitzel R; Ben-Ari J; Chander P; Gammon D; Goodman AI; Head R
    Clin Exp Hypertens A; 1988; 10(2):229-47. PubMed ID: 2836114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressin and sympathetic nervous functions both contribute to development and maintenance of hypertension in DOCA-salt rats.
    Takata Y; Yamashita Y; Takishita S; Fujishima M
    Clin Exp Hypertens A; 1988; 10(2):203-27. PubMed ID: 3370846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased endothelin binding and [Ca2+]i signaling in microvessels of DOCA-salt hypertensive rats.
    Molero MM; Giulumian AD; Reddy VB; Ludwig LM; Pollock JS; Pollock DM; Rusch NJ; Fuchs LC
    J Hypertens; 2002 Sep; 20(9):1799-805. PubMed ID: 12195122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role of magnesium.
    Gopalakrishnan V; Triggle CR; Sulakhe PV; McNeill JR
    Endocrinology; 1986 Mar; 118(3):990-7. PubMed ID: 3004905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular effects of intracerebroventricular injection of vasopressin in unanaesthetized normotensive and DOCA-salt hypertensive rats.
    Berecek KH; Mah SC; Baum P; Hofbauer KG
    J Hypertens Suppl; 1984 Dec; 2(3):S29-31. PubMed ID: 6599674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptors for Arg8-vasopressin, angiotensin II, and atrial natriuretic peptide in the mesenteric vasculature of pregnant rats.
    Parent A; Schiffrin EL; St-Louis J
    Can J Physiol Pharmacol; 1991 Feb; 69(2):137-44. PubMed ID: 1647264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of magnocellular vasopressin mRNA in rats with deoxycorticosterone-acetate induced salt appetite.
    Grillo CA; Saravia F; Ferrini M; Piroli G; Roig P; García SI; de Kloet ER; De Nicola AF
    Neuroendocrinology; 1998 Aug; 68(2):105-15. PubMed ID: 9705577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased vasopressinergic activity following DOCA administration in the rat.
    Chen YF; Lindheimer MD; Oparil S
    Brain Res Bull; 1986 Jan; 16(1):93-8. PubMed ID: 3955390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pressor response to vasopressin and impaired baroreflex function in DOC-salt hypertension.
    Matsuguchi H; Schmid PG
    Am J Physiol; 1982 Jan; 242(1):H44-9. PubMed ID: 7058912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats: role of endothelin.
    Intengan HD; Park JB; Schiffrin EL
    Hypertension; 1999 Oct; 34(4 Pt 2):907-13. PubMed ID: 10523383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal function contributes to antihypertensive effect of vasopressin in DOCA-salt but not spontaneous hypertension.
    Wang H; McNeill JR
    Am J Physiol; 1994 Nov; 267(5 Pt 2):H1842-50. PubMed ID: 7977814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
    Nishimura M; Ohtsuka K; Sakamoto M; Nanbu A; Takahashi H; Yoshimura M
    J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pressor response to vasopressin and norepinephrine in DOC-salt hypertensive and prehypertensive rats.
    Ouchi Y; Yazaki Y; Tsai RC; Ashida T
    Tohoku J Exp Med; 1988 Feb; 154(2):125-33. PubMed ID: 3381222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological action and binding sites for vasopressin on the mesenteric artery from normal and sodium-depleted rats.
    St-Louis J; Schiffrin EL
    Life Sci; 1984 Oct; 35(14):1489-95. PubMed ID: 6090837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Withdrawal-induced antihypertensive effect of vasopressin in Doca-salt hypertension.
    Chiu EK; McNeill JR
    Am J Hypertens; 1989 Jun; 2(6 Pt 1):458-61. PubMed ID: 2757802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The significance of vasopressin as a pressor agent.
    Hofbauer KG; Studer W; Mah SC; Michel JB; Wood JM; Stalder R
    J Cardiovasc Pharmacol; 1984; 6 Suppl 2():S429-38. PubMed ID: 6206352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.